Ribomunyl 0.75mg pills №4

Active ingredient and dosage form

round, biconvex, white or almost white, odorless.
1 pill (1/3 dose) contains:
bacterial ribosomes titrated to 70% ribonucleic acid - 250 μg,
(including Klebsiella pneumoniae ribosomes - 3.5 shares, Streptococcus pneumoniae - 3.0 shares, Streptococcus pyogenes - 3.0 shares, Haemophilus influenzae - 0.5 shares); membrane proteoglycans
Klebsiella pneumoniae - 375 mcg;
other components: silicon, Magnesium stearate, sorbitol;
12 pcs. in blister, 1 blister in a carton box.

Pills round, biconvex, white or almost white, odorless.
1 pill (1 dose) contains:
bacterial ribosomes, titrated to 70% ribonucleic acid - 750 μg,
(including Klebsiella pneumoniae ribosomes - 3.5 shares, Streptococcus pneumoniae - 3.0 shares, Streptococcus pyogenes - 3.0 shares, Haemophilus influenzae - 0.5 shares); membrane proteoglycans
Klebsiella pneumoniae - 1.125 mg;
other components: silicon, magnesium stearate, sorbitol;
4 things. in blister, 1 blister in a carton box.

white color, odorless.
1 package (1 dose) contains:
bacterial ribosomes, titrated to 70% ribonucleic acid - 750 μg,
(including Klebsiella pneumoniae ribosomes - 3.5 shares, Streptococcus pneumoniae - 3.0 shares, Streptococcus pyogenes - 3.0 shares, Haemophilus influenzae - 0.5 shares); membrane proteoglycans
Klebsiella pneumoniae - 1.125 mg;
other components: polyvidone, D-mannitol.
500 mg in laminated paper bags, 4 bags in a carton box.

Tab.: - P No. 011369/01, 10.06.05
granules d / prigot. r-ra d / ingestion - P №011369/02, 10.06.05

Mechanism of action

Ribomunil, being the ribosomal-proteoglycan complex of the most common pathogens of upper respiratory tract and respiratory tract infections, belongs to the correctors of specific and nonspecific immunity.
The ribosomes in its composition contain antigens identical to the surface antigens of bacteria, and when ingested, they cause the formation of specific antibodies to these pathogens (a vaccine effect). Membrane proteoglycans stimulate nonspecific immunity, which is manifested in increased phagocytic activity of macrophages and polynuclear leukocytes, an increase in factors of nonspecific resistance. The drug stimulates the function of T-and B-lymphocytes, the production of serum and secretory immunoglobulins such as IgA, interleukin-1, as well as alpha- and gamma-interferons. This explains the preventive effect of Ribomunyl on respiratory viral infections.
The use of Ribomunyl in the complex therapy allows to increase the effectiveness and shorten the duration of treatment, significantly reduce the need for the use of antibiotics, bronchodilators, increase the period of remission.

Indications and usage

- prevention and treatment of recurrent infections of upper respiratory tract (otitis media, rhinitis, sinusitis, sore throat, pharyngitis, laryngitis) in patients older than 6 months;
- prevention and treatment of recurrent respiratory tract infections (chronic bronchitis, tracheitis, pneumonia, infectious dependent bronchial asthma) in patients older than 6 months;
- prevention of recurrent infections in patients at risk (often and long-term ill, before the start of the autumn-winter season, especially in environmentally unfriendly regions, patients with chronic diseases of the upper respiratory tract, chronic bronchitis, bronchial asthma, including the elderly and children older than 6 months).

Contraindications

- autoimmune diseases;
- Hypersensitivity to the drug.

Dosage and administration

Adults and children over 6 months. the drug is prescribed 1 time per day in the morning on an empty stomach.
A single dose (regardless of age) is 3 tab. 0.25 mg (1/3 single dose), or 1 tab. at 0.75 mg (with one dose), or granules from 1 sachet (previously dissolved in boiled water at room temperature).
In the first month of treatment and / or prophylactically, Ribomunyl is taken daily for the first 4 days of each week for 3 weeks. In the next 5 months, the first 4 days of each month.
Young children are recommended to prescribe the drug in the form of granules.
It is recommended to carry out three-month preventive courses of treatment 2 times.
per year, six months - once a year.

Adverse reactions

On the part of the body as a whole: transient hypersalivation at the beginning of treatment.
Allergic reactions: in isolated cases - urticaria, angioedema.
Gastrointestinal: extremely rare - nausea, vomiting, diarrhea.
Side effects are rare and do not require discontinuation of the drug.

Pregnancy and breastfeeding

Special studies on the safety and efficacy of Ribomunyl during pregnancy and lactation have not been conducted.
The use of Ribomunyl during pregnancy and lactation (breastfeeding) is possible only after assessing the intended benefits to the mother and the potential risk to the fetus and child.

Patients should be warned about the possibility of a transient increase in body temperature for 2-3 days, which is a manifestation of the therapeutic effect of the drug and does not, as a rule, require discontinuation of treatment. An increase in temperature can sometimes be accompanied by minor and transient symptoms of infections of upper respiratory tract infections.

Drug Interactions

To date, the clinically significant drug interaction of the drug Ribomunyl is not described. The use of the drug can be combined with other drugs.

Storage conditions

The drug should be stored and transported at a temperature of from 15 ° to 25 ° C.